- Conditions
- Hepatitis C Virus
- Interventions
- BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 8,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plaque Psoriasis
- Interventions
- ILV-095 300 mg in a 4 to 1 ratio
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Miami Gardens, Florida • South Miami, Florida • Indianapolis, Indiana + 3 more
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 24 Hours to 120 Hours
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Omacetaxine mepesuccinate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Ulcerative Colitis
- Interventions
- Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- AGA2115, Placebo
- Drug · Other
- Lead sponsor
- Angitia Incorporated Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
- Conditions
- Askin Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Hematopoietic Stem Cells
- Interventions
- Vedolizumab Placebo, Vedolizumab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more
- Conditions
- Constipation
- Interventions
- Tegaserod
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- ABT-510/Thrombospondin-1 mimetic
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- solifenacin succinate
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 104
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- VELCADE TM (bortezomib) for Injection
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Berkeley, California • Duarte, California + 26 more
- Conditions
- Abdominal Discomfort, Bloating
- Interventions
- B. infantis 35624, placebo
- Dietary Supplement
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Rockford, Illinois • Indianapolis, Indiana + 7 more
- Conditions
- Neoplasms
- Interventions
- Gene-modified (GM) T cell therapy
- Genetic
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
- Conditions
- Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
- Interventions
- Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 9 Months to 18 Months
- Enrollment
- 1,394 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
- Conditions
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
- Interventions
- Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Cerebrospinal Fluid Leak
- Interventions
- EVICEL Fibrin Sealant, Hydrogel sealant
- Biological · Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more
- Conditions
- Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Interventions
- Sitagliptin
- Drug
- Lead sponsor
- Sherif S. Farag
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- End Stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Placebo, secukinumab (AIN457), etanercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
- Conditions
- Plaque Psoriasis
- Interventions
- Calcitriol 3 mcg/g ointment
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- San Diego, California • Indianapolis, Indiana • Ann Arbor, Michigan + 5 more
- Conditions
- Prostate Cancer
- Interventions
- ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana